Advocates request Cepheid immediately reduce the price of Xpert tests to $5, inclusive of service and maintenance; Cepheid claims costs for each Xpert cartridge "substantially exceed" the requested price target of $5, but does not provide evidence to support this claim.

Pretomanid receives FDA approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.

Advocates request responsible investment in pretomanid promoting transparency and equitable access.

Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9^th South African AIDS Conference.

Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Advocates call on Indian Minister of Health to discontinue and phase out the drug donations of bedaquiline offered by Johnson & Johnson.

Advocates call for minimizing the use of injectable agents and scaling up universal drug susceptibility testing.

Advocates call for removal of regulatory barriers, which contributed to the ongoing national stock out of GeneXpert MTB/RIF cartridges.

Advocates request that bedaquiline become part of the standard treatment regimen for drug-resistant TB in India.